Holen Sie sich die Stockscreener-App
6.97
0.71%
-0.05
Handel nachbörslich:
6.96
-0.010
-0.14%
Schlusskurs vom Vortag:
$7.02
Offen:
$7.115
24-Stunden-Volumen:
19,953
Relative Volume:
0.93
Marktkapitalisierung:
$28.20M
Einnahmen:
$8.30M
Nettoeinkommen (Verlust:
$-52.26M
KGV:
0.1772
EPS:
39.3379
Netto-Cashflow:
$-17.14M
1W Leistung:
+1.90%
1M Leistung:
-6.44%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$6.922
$7.26
1-Wochen-Bereich:
$6.70
$7.65
52-Wochen-Spanne:
$6.67
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Firmenname
Kyntra Bio Inc
Sektor
Branche
Telefon
415-978-1200
Adresse
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
6.97 | 28.40M | 8.30M | -52.26M | -17.14M | 39.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-26 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2023-06-26 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Hochstufung | Stifel | Hold → Buy |
| 2023-01-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-09-22 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-07-16 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-03-31 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-03-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-26 | Eingeleitet | Raymond James | Underperform |
| 2020-07-10 | Fortgesetzt | Stifel | Buy |
Alle ansehen
Kyntra Bio Inc Aktie (KYNB) Neueste Nachrichten
KYNB: Lead oncology and anemia programs advance with strong data, regulatory clarity, and commercial promise - TradingView
Kyntra Bio : Corporate Presentation – March 2026 - marketscreener.com
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results - Bitget
KYNB Price History for Kyntra Bio Stock - Barchart.com
KYNB | Kyntra Bio, Inc. Common Institutional Ownership - Quiver Quantitative
Kyntra Bio reports prostate cancer trial results at ASCO GU - Investing.com South Africa
What's Going On With Kyntra Bio Stock Tuesday? - Bitget
Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246 - TipRanks
Kyntra Bio reports prostate cancer trial results at ASCO GU By Investing.com - Investing.com Australia
KYNB to Present FG-3246 Trial Data at ASCO GU 2026 - GuruFocus
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - marketscreener.com
Kyntra Bio to Participate in Upcoming Investor Conferences - The Manila Times
Kyntra Bio Charts a New Course in Oncology - AD HOC NEWS
KYNB SEC FilingsKYNTRA BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
KYNB Stock Price, Forecast & Analysis | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio (KYNB) Stock Price, News & Analysis - MarketBeat
What is the current Price Target and Forecast for Kyntra Bio Inc (KYNB) - Zacks Investment Research
symbol__ Stock Quote Price and Forecast - CNN
KYNB: Kyntra Bio IncFull Company Report - Zacks Investment Research
FibroGen rebrands as Kyntra Bio, refocuses on oncology - TipRanks
FibroGen announces rebrand as Kyntra Bio - TipRanks
FibroGen stock rises after announcing rebrand to Kyntra Bio - Investing.com
FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB - Investing.com
FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewswire
Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
FibroGen Sells China Unit To AstraZeneca And Refocuses - Finimize
FibroGen (NASDAQ: FGEN) sets Q3 results; 5:00 PM ET conference call Monday - Stock Titan
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million - GlobeNewswire
Major Regulatory Win: FibroGen's $815M China Business Sale to AstraZeneca Gets Green Light from Regulators - Stock Titan
FibroGen Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
FGENFibrogen Inc Latest Stock News & Market Updates - Stock Titan
FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewswire
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - marketscreener.com
FibroGen: Q1 Earnings Snapshot - marketscreener.com
FGEN Stock Price, News & Analysis - Stock Titan
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - marketscreener.com
FGEN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
FibroGen: Q4 Earnings Snapshot - marketscreener.com
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - marketscreener.com
FibroGen, Inc. Announces Cessation of Christine L. Chung as Senior Vice President, China Operations - marketscreener.com
FibroGen, Inc. Appoints David DeLucia as Chief Financial Officer - marketscreener.com
FibroGen: Q3 Earnings Snapshot - marketscreener.com
FibroGen to Report Third Quarter 2024 Financial Results - marketscreener.com
Kyntra Bio Inc (KYNB) Stock Price Quote Today & Current Price Chart - Capital.com
Finanzdaten der Kyntra Bio Inc-Aktie (KYNB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):